← INTEGRA LIFESCIENCES HOLDINGS CORP (IART) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
Surgical & Medical Instruments & Apparatus · market cap $1.2B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-29 (est.)
Earnings
Pipeline
4
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Integra LifeSciences Holdings Corp (IART) is a surgical and medical instruments company with a market cap of ~$1.5B and ~$236.8M in cash against net debt of $533.3M. Despite a core medtech business generating ~$1.6B in annual revenue, the company reported a steep net loss of $516M in 2025 after posting modest profits in prior years. Its pipeline includes two Phase 3 bowel preparation assets, which appear non-core relative to its primary surgical/medical device identity.
The catalyst path
- 2026-10-29 (est.)Earningsimp 5/10
- 2027-08-31 (est.)Phase 2 · BioDFence G3 Placental Tissue Membraneimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Picosulfate sodium, magnesium oxide, citric acid | Phase 3 | Bowel Preparation Before Colonoscopy |
| Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) | Phase 3 | Bowel Preparation |
| NorLeu3-A(1-7) in a gel formulation | Phase 2 | Foot Ulcer, Diabetic |
| BioDFence G3 Placental Tissue Membrane | Phase 2 | Prostate Cancer |
Price & technical context
3-month
-9.0%
6-month
+72.8%
12-month
+19.4%
52-wk range
$8.90–$19.85
vs 50-day MA
-3.8%
vs 200-day MA
+15.9%
Realized vol
61.1%
Max drawdown
-66.7%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IART (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.